Regents Of The University Of California Arvinas, Inc. Transaction History

Regents Of The University Of California

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$36.01 - $74.24 $2.61 Million - $5.39 Million	-72,616 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$60.27 - $81.57 $1.14 Million - $1.55 Million	-18,960 Reduced 20.7%	72,616 $4.89 Million
Q4 2021 Jan 24, 2022	BUY	$65.85 - $96.21 $939,942 - $1.37 Million	14,274 Added 18.47%	91,576 $7.52 Million
Q3 2021 Oct 20, 2021	BUY	$73.2 - $107.87 $5.66 Million - $8.34 Million	77,302 New	77,302 $6.35 Million
Q4 2020 Jan 21, 2021	SELL	$20.19 - $84.93 $289,383 - $1.22 Million	-14,333 Closed	0 $0
Q3 2020 Oct 21, 2020	BUY	$22.99 - $36.34 $329,515 - $520,861	14,333 New	14,333 $338,000
Q4 2019 Feb 10, 2020	SELL	$15.39 - $44.38 $320,619 - $924,568	-20,833 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$15.96 - $23.8 $332,494 - $495,825	20,833 New	20,833 $458,000

221

68.8M

166K

31.3K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.43B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

Stay updated on Regents Of The University Of California with notifications on news.